Humoral responses to BNT162b2 SARS-CoV-2 and hepatitis B vaccines are associated in patients on maintenance hemodialysis: a single-center experience in Belgium
Maintenance hemodialysis (HD) patients are at high risk for life-threatening coronavirus disease 2019 (COVID-19). Recent studies have documented a strong humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in this population, even in older patients, in contrast to kidney transplant recipients. Previous reports have also shown a poor humoral response after hepatitis B virus (HBV) vaccination in chronic kidney disease patients with comorbidities (e.g. older age, diabetes, immunosuppression). We therefore hypothesized that this weak response to the HBV... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
Oxford University Press
|
Schlagwörter: | Transplantation / Nephrology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26603762 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/254252 |
Maintenance hemodialysis (HD) patients are at high risk for life-threatening coronavirus disease 2019 (COVID-19). Recent studies have documented a strong humoral response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in this population, even in older patients, in contrast to kidney transplant recipients. Previous reports have also shown a poor humoral response after hepatitis B virus (HBV) vaccination in chronic kidney disease patients with comorbidities (e.g. older age, diabetes, immunosuppression). We therefore hypothesized that this weak response to the HBV vaccine could serve as a potential indicator of response to SARS-CoV-2 vaccination. However, data linking humoral responses to both vaccines remains scarce and contradictory [.].